Kan, David

Antibody targeting of E3 ubiquitin ligases for receptor degradation

Marei, H., Tsai, W.-T. K., Kee, Y.-S., Ruiz, K., He, J., Cox, C., Sun, T., Penikalapati, S., Dwivedi, P., Choi, M., et al. (2022) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 273

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Luo, F. R., Yang, Z., Camuso, A., Smykla, R., McGlinchey, K., Fager, K., Flefleh, C., Castaneda, S., Inigo, I., Kan, D., et al. (2006) · Clinical Cancer Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 151

Disruption of IRE1α through its kinase domain attenuates multiple myeloma

Harnoss, J. M., Le Thomas, A., Shemorry, A., Marsters, S. A., Lawrence, D. A., Lu, M., Chen, Y.-C. A., Qing, J., Totpal, K., Kan, D., et al. (2019) · Proceedings of the National Academy of Sciences

Endoplasmic Reticulum Stress and DiseaseMultiple Myeloma Research and Treatments

Cited by 109